title: A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
abstract: T cell prolymphocytic leukemia (T-PLL) is a rare mature T cell lymphoproliferative disease. It has been associated with an aggressive course, a poor response to conventional chemotherapy and a short median survival. Here we present a rare case of concurrent T-PLL and Kaposi sarcoma who achieved a complete hematologic and cytogenetic remission after a very short course of treatment with alemtuzumab. A review of T-PLL was done. In this review, clinical features, laboratory features and current therapeutic strategies of T-PLL are presented.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Howard University Hospital, Washington, DC 20060, USA. rabipaul@gmail.com
authors.forename: R N
authors.initials: RN
authors.lastname: Paul
authors.forename: L
authors.initials: L
authors.lastname: Alizadeh
authors.forename: O I
authors.initials: OI
authors.lastname: Ajayi
authors.forename: H
authors.initials: H
authors.lastname: Karpurapu
authors.forename: C
authors.initials: C
authors.lastname: Ganesan
authors.forename: L
authors.initials: L
authors.lastname: Taddesse-Heath
authors.forename: A
authors.initials: A
authors.lastname: Aggarwal
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000074301:CD52 Antigen; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000532:radiotherapy / Q000628:therapy*; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab